Mineralocorticoid receptor antagonists (MRAs) are recommended, in addition to an angiotensin-converting enzyme inhibitors (ACE-I) and a beta-blocker, in all patients with HFrEF to reduce mortality and the risk of HF hospitalization [2]. This evidence concerns the gene NR3C2 and hydrops fetalis.